Literature DB >> 15451562

Beta A versus beta B: is it merely a matter of expression?

Thomas B Thompson1, Robert W Cook, Stacey C Chapman, Theodore S Jardetzky, Teresa K Woodruff.   

Abstract

Activins are members of the transforming growth factor (TGF) beta (beta) superfamily of proteins that function in a wide array of physiological processes. Like other TGFbeta ligands, activins are biologically active as dimers. An activin molecule is comprised of two beta-subunits, of which four isoforms have been identified: betaA, betaB, betaC, and betaE. The most widely studied activins to date are activin A (betaA/betaA), activin B (betaB/betaB), and activin AB (betaA/betaB). Inhibin is a naturally occurring activin antagonist that consists of an alpha-subunit disulfide-linked to one of the activin beta-subunits, producing inhibin A (alpha/betaA), or inhibin B (alpha/betaB). The development of assays distinguishing between different forms of activins and inhibins, along with knock-in and knock-out models, have provided evidence that the betaA- and betaB-subunits have independent and separate roles physiologically. Additionally, evaluation of ligand-receptor interactions indicates significant differences in receptor affinity between activin isoforms, as well as between inhibin isoforms. In this review we explore the differences between activin/inhibin betaA- and betaB-subunits, including expression patterns, binding properties, and the specific structural aspects of each. From the growing pool of knowledge regarding activins and inhibins, the emerging data support the hypothesis that betaA- and betaB-subunits are functionally differently.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15451562     DOI: 10.1016/j.mce.2004.02.007

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  23 in total

Review 1.  The role of activin in mammary gland development and oncogenesis.

Authors:  Karen A Dunphy; Alan L Schneyer; Mary J Hagen; D Joseph Jerry
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-04-08       Impact factor: 2.673

2.  Inhibin α-subunit N terminus interacts with activin type IB receptor to disrupt activin signaling.

Authors:  Jie Zhu; S Jack Lin; Chao Zou; Yogeshwar Makanji; Theodore S Jardetzky; Teresa K Woodruff
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

Review 3.  A FoxL in the Smad house: activin regulation of FSH.

Authors:  Djurdjica Coss; Pamela L Mellon; Varykina G Thackray
Journal:  Trends Endocrinol Metab       Date:  2010-07-02       Impact factor: 12.015

Review 4.  Inhibin at 90: from discovery to clinical application, a historical review.

Authors:  Yogeshwar Makanji; Jie Zhu; Rama Mishra; Chris Holmquist; Winifred P S Wong; Neena B Schwartz; Kelly E Mayo; Teresa K Woodruff
Journal:  Endocr Rev       Date:  2014-07-22       Impact factor: 19.871

5.  Detection of differentially expressed glycogenes in trabecular meshwork of eyes with primary open-angle glaucoma.

Authors:  Shiri Diskin; Janardan Kumar; Zhiyi Cao; Joel S Schuman; Tim Gilmartin; Steven R Head; Noorjahan Panjwani
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-04       Impact factor: 4.799

6.  Conditional activin receptor type 1B (Acvr1b) knockout mice reveal hair loss abnormality.

Authors:  Wanglong Qiu; Xiaojun Li; Hongyan Tang; Alicia S Huang; Andrey A Panteleyev; David M Owens; Gloria H Su
Journal:  J Invest Dermatol       Date:  2010-12-30       Impact factor: 8.551

7.  The role of activin A and Akt/GSK signaling in ovarian tumor biology.

Authors:  Thuy-Vy Do; Lena A Kubba; Monica Antenos; Alfred W Rademaker; Charles D Sturgis; Teresa K Woodruff
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

8.  Phylogenomic analyses reveal the evolutionary origin of the inhibin alpha-subunit, a unique TGFbeta superfamily antagonist.

Authors:  Jie Zhu; Edward L Braun; Satomi Kohno; Monica Antenos; Eugene Y Xu; Robert W Cook; S Jack Lin; Brandon C Moore; Louis J Guillette; Theodore S Jardetzky; Teresa K Woodruff
Journal:  PLoS One       Date:  2010-03-04       Impact factor: 3.240

Review 9.  Activins and activin antagonists in hepatocellular carcinoma.

Authors:  Alev Deli; Emanuel Kreidl; Stefan Santifaller; Barbara Trotter; Katja Seir; Walter Berger; Rolf Schulte-Hermann; Chantal Rodgarkia-Dara; Michael Grusch
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

10.  Conditional deletion of the retinoblastoma (Rb) gene in ovarian granulosa cells leads to premature ovarian failure.

Authors:  Claudia Andreu-Vieyra; Ruihong Chen; Martin M Matzuk
Journal:  Mol Endocrinol       Date:  2008-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.